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 ABSTRACT 
Human T cell lymphotropic virus type 1 (HTLV-1) is the etiological agent of a severe 
form of T cell neoplasia called Adult T cell Leukaemia (ATL) and of a neurologic 
disorder designated HTLV-1-associated myelopathy/tropical spastic paraparesis 
(HAM/TSP). The HBZ oncoprotein encoded by the minus strand of the HTLV-1 is 
thought to play an important role in both diseases. 
The recent isolation in our laboratory of the first described monoclonal antibody 
against HBZ protein has now permitted to investigate in detail the cellular and 
biochemical features of endogenous HBZ. In this direction our laboratory has recently 
established that HBZ is a nuclear protein in cells of ATL patients. My thesis was 
predominantly focussed in expanding the analysis particularly in HAM/TSP patients, 
to assess similarities and/or diversities of HBZ subcellular distribution with respect to  
ATL patients and asymptomatic HTLV-1 carriers.  
Expression and localization of HBZ in peripheral blood mononuclear cells (PBMC) of 
ATL, HAM/TSP patients and in HTLV-1 asymptomatic carriers (AC) was analyzed 
by immunohistochemistry and confocal microscopy using the anti-HBZ 4D4-F3 mAb.  
Analysis of patients with HAM/TSP unequivocally showed that HBZ-positive cells 
presented an exclusive, never reported, cytoplasmic localization of the viral oncogenic 
protein. Interestingly, experiment with leptomycin B indicated that HBZ could not 
shuttle between cytoplasm and nucleus. This strict HBZ cytoplasmic localization was 
at variance with the distribution of the other HTLV-1 oncogenic protein, Tax-1, that 
could localize both in the cytoplasm and the nucleus, and could be sequestered totally 
in the nucleus after leptomycin B treatment of the cells. Additional extensive analysis 
of cells from ATL patients and asymptomatic recipients confirmed, instead, a nuclear 
localization of HBZ. 
I further supported this finding by studying HBZ and Tax-1 in the CIB cell line, a 
CD4+ IL-2-dependent T cell line derived from an HAM/TSP patient. The vast majority 
of CIB cells express significant amounts of HBZ exclusively  in the cytoplasm, mostly 
in a speckle-like fashion. Tax-1 instead was expressed in 30% of the cells, either as a 
 diffuse reticulum or distributed in a speckled-like fashion mainly in the cytoplasm. 
Interestingly, in cells co-expressing cytoplasmic HBZ and Tax-1, the two proteins did 
not co-localize, suggesting that they do not interact in vivo.  
Our results establish for the first time a distinctive and diverse pattern of sub-cellular 
localization of endogenous HBZ protein. Furthermore, and of potential importance in 
the pathogenesis of HTLV-1-associated diseases, our data suggest that the endogenous 
localization of HBZ protein in different cellular compartments may correlate with the 
different forms of the HTLV-1-mediated diseases.  
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1 INTRODUCTION 
 
1.1 HTLV-1 infection and diseases 
 
The human T-cell lymphotropic virus type 1 (HTLV-1) is the first described human 
retrovirus and belongs to the deltaviridae family, subfamily oncovirus type C (Poiesz 
et al., 1980). It is estimated that HTLV-1 has infected 10-20 million people world wide 
(Gessain and Cassar, 2012). 
HTLV-1 infects primarily CD4+ T cells although other cell types such as CD8+ T cells, 
dendritic cells and B cells can also be infected, although more rarely. 
As stated above, HTLV-1 was the first discovered human retrovirus associated with 
diseases (Poiesz et al., 1980). Indeed the virus is the etiological agent of a severe, still 
untreatable, form of adult T cell leukemia/lymphoma (ATL) as well as  inflammatory 
syndromes (HTLV-1-associated myelopathy/tropical spastic paraparesis and uveitis 
among others). Finally, HTLV-1 is found associated also to opportunistic infections 
(including Strongyloides stercoralis hyperinfection and others).  
  
1.1.1 Adult T-Cell Leukemia/Lymphoma 
ATL is an aggressive lymphoproliferative malignancy of peripheral T cells, with short 
survival in its acute form and an incidence of less than 5% in HTLV-1-infected people. 
It was initially described in Japan and later in the Caribbean region and South America. 
In Europe and the United States, ATL was diagnosed in immigrants from regions of 
endemicity (Goncalves et al., 2010). 
ATL is a heterogeneous, yet very aggressive, malignant disease clinically divided into 
four subtypes: acute, chronic, smoldering type and lymphoma type. Typical ATL cells 
have convoluted nuclei with homogeneous and condensed chromatin, small or absent 
nucleoli, and agranular and basophilic cytoplasm. The characteristic shape of the 
nucleus of ATL cells let to the designation of these cells as “flower cells”. 
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The rate of survival varies depending on the subtype: 4 to 6 months for the acute type, 
9 to 10 months for the lymphoma type, 17 to 24 months for the chronic type, and 34 
months to more than 5 years for the smoldering type. 
1.1.2 HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis 
HAM/TSP is a chronic meningomyelitis of the gray and white matter in the spinal cord, 
with perivascular demyelination and axonal degeneration (Cooper et al., 2009) with an 
incidence of less than 3% in HTLV-1-infected people. Patients will develop a slowly 
progressive spastic paraparesis, without remissions, with high impairment of gait, 
autonomic dysfunction of bladder and bowel, and profound repercussions on their 
abilities and quality of life. Women are affected more frequently than men, and the 
disease onset occurs in adulthood. 
1.1.3 HTLV-1-Associated Uveitis 
Ophthalmological disturbances related to HTLV-1 infection include vasculitis, 
exudation or degeneration of the peripheral retina, and keratoconjunctivitis sicca, as 
well as a typical form of uveitis (HTLV-1-associated uveitis or HAU) (Pinheiro et al., 
2006) 
Middle-aged HTLV-1-infected adults of both genders are the target population. HAU 
is characterized by a granulomatous or nongranulomatous reaction accompanied by 
vitreous opacities and retinal vasculitis with rare exudative retinochoroidal alterations 
in one or both eyes. It can occur as the only HTLV-1 manifestation or can be associated 
with HAM/TSP. Uveitis usually occurs as an isolated ophthalmological alteration. 
 
 
Although the factors that cause the different manifestations of HTLV-1 infection are 
not fully understood, previous population studies suggest that both viral and host 
genetic factors influence the outcome of infection 
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1.2 The HTLV-1 Virus 
 
HTLV-1 is an enveloped virus that is approximately 100 nm in diameter (Figure 1) 
 
               
 
 
 
Figure 1. Electron Micrograph of HTLV-1. Arrows indicate the HTLV-1 virions. Image Adapted 
from Centers for Disease Control and Prevention, USA. 
 
 
The inner membrane of the virion envelope is lined by the viral matrix protein (MA) 
(Figure 2). This structure encloses the viral capsid (CA), which carries two identical 
strands of the genomic RNA as well as functional protease (Pro), integrase (IN), and 
reverse transcriptase (RT) enzymes. A newly synthesized viral particle attaches to the 
target cell receptor through the viral envelope (Env) and enters via fusion, which is 
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followed by the uncoating of the capsid and the release of its contents into the cell 
cytoplasm. The viral RNA is reverse transcribed into double stranded DNA by the RT. 
This double stranded DNA is then transported to the nucleus and eventually integrated 
into the host chromosome forming the provirus. The provirus contains the promoter 
and enhancer elements for transcription initiation in the long terminal repeats (LTR); 
the polyadenylation signal for plus strand transcription is located in the 3′LTR 
(Kannian and Green, 2010) 
 
 
 
          
                               
 
Figure 2. Schematic structure of HTLV-1. The surface glycoprotein (SU) is responsible for binding 
to receptors of host cells. The transmembrane protein (TM) anchors SU to the virus. NC is a nucleic 
acid–binding protein found in association with the viral RNA. A protease (PR) cleaves the 
polyproteins encoded by the gag, pol, and env genes into their functional components. RT is reverse 
transcriptase, The matrix protein (MA) is a Gag protein closely associated with the lipid of the 
envelope. The capsid protein (CA) forms the major internal structure of the virus, the core shell. 
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There are four known strains of HTLV including HTLV type 1 (HTLV-1), HTLV-2, 
HTLV-3 and HTLV-4. HTLV-1 and HTLV-2 were discovered in the 1980s (Poiez et 
al., 1980). HTLV-3 and HTLV-4 were only recently described (Mahieux and Gessain, 
2009) (Nicolas et al., 2015). So far, the only strain that is clearly associated with human 
diseases is HTLV-1. 
The most important routes of HTLV-1 transmission are breastfeeding, sexual 
intercourse, and blood contact, including the transfusion of infected cellular products 
or sharing of needles and syringes (Proietti et al., 2005) 
 
1.3 HTLV-1 Genome 
 
The genome organization of HTLV-1 is similar to all common retroviruses; in fact, 
HTLV-1 has gag, pro, pol and env genes that respectively encodes for structural 
protein of the virion (gag), the viral protease (pro) the reverse transcriptase enzyme 
(pol) and the virion envelope glycoprotein (env) (Figure 3). 
In addition to essential retroviral components, HTLV-1 provirus has a unique region 
between env and the 3′LTR; and this region is named pX (Franchini et al., 2003). The 
pX region encodes viral regulatory and accessory proteins Tax, Rex, p8, p12, p13, p30, 
p21, and HTLV-1 bZIP factor (HBZ) which are implicated in viral infectivity and the 
proliferation of infected cells (Gaudray et al., 2002; Mota-Miranda et al., 2013; Satou 
et al., 2006). Tax is recognized as a potent oncoprotein, since it immortalizes human 
primary T cells by itself, and Tax transgenic mice form tumors (Tanaka et al., 1990). 
Nevertheless, tax transcripts are detected in only ~40% of ATL cases (Takeda et al., 
2004). Recently, the viral factor, HBZ, has been shown to have an oncogenic effect in 
vivo (Satou et al., 2011). Expression of HBZ is conserved in all ATL cells, strongly 
suggesting that it contributes to leukemogenesis (Yasunaga and Matsuoka, 2011). 
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Figure 3. Schematic representation of HTLV-1 genome. p19 and p24 are the major core 
proteins of HTLV. Gray: LTR, Long Terminal Repeat; Coding regions for all major proteins: 
gag, group-specific antigen; pro, protease; pol, polymerase; env, envelope; rex, regulator of 
expression; tax, transactivator; HBZ, HTLV basic leucine zipper. The pink letters indicate the 
positions of the major proteins encoded by the corresponding genes, including the MA 
(matrix), CA (capsid), NC (nucleocapsid) proteins of gag, the PR (protease), RT (reverse 
transcriptase), IN (integrase) enzymes of pol and the SU (surface) and TM (transmembrane) 
proteins of env. (Zhang et al., 2017) 
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 1.4 The HTLV-1 bZIP Protein (HBZ) 
 
HBZ protein contains a bZIP domain in addition to an activation (N-terminus) and a 
central domain (Figure 4) (Gaudray et al., 2002).  
 
 
                           
 
Figure 4. Schematic representation of HBZ domains. HBZ has three domains: activation domain 
(AD), central domain (CD), and basic ZIP domain (bZIP). Functions of each domain are listed. (Zhao 
and Matsuoka, 2012) 
 
There are two different isoforms of this protein: a spliced form containing 206 amino 
acids (sp1) and an unspliced form with 209 amino acids (us ) (Murata et al., 2006). The 
sp1 form is more abundant and is found in almost all ATL patients (Satou et al., 2006). 
Spliced HBZ is more potent than unspliced HBZ in inhibiting transcription from viral 
5′ LTR. Indeed, experiments using cells transfected with tagged HBZ have shown that 
HBZ interacts with CREB-2 via its bZIP domain resulting in strong inhibition of the 
CREB-2/Tax-1 interaction instrumental for the activation of HTLV-1 LTR (Figure 5). 
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Figure 5. Schematic illustration of the expression and the activities of the HBZ RNA and protein 
in HTLV-1-infected cells. The effect of HTLV-1 basic leucine zipper factor (HBZ) on CREB2 and 
activating protein 1 (AP1) are shown. The effects of HBZ RNA on the E2F1 transcription factor and 
downstream E2F1-responsive genes are also shown. Current evidence suggests that the HBZ protein 
might antagonize the positive transcriptional effect of Tax on the HTLV-1 (human T-cell leukemia 
virus type 1) long terminal repeat (LTR). CREB, cyclic AMP responsive element binding protein 
(Matsuoka and Jeang, 2007) 
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In addition to interacting with CREB-2, similar experiments have shown that HBZ 
binds to different proteins of the JUN family via its bZIP domain (Basbous et al., 2003). 
The binding to JunB and cJun induces a sequestration of these factors in nuclear bodies 
or an accelerated degradation of them. As a result, HBZ reduces the cJun/JunB-
mediated transcriptional activation of a series of genes. Conversely, the binding of 
HBZ to JunD does not inhibit the JunD-mediated transcriptional activation of target 
genes; indeed HBZ-JunD complex upregulates even the expression of HBZ encoding 
gene (Gazon et al., 2012). Interestingly, in many cases HBZ exerts opposite effects 
with respect to Tax-1 on signaling pathways (Matsuoka and Yasunaga, 2013). HBZ 
interacts with the KIX domain of p300/CBP to deregulate their interaction with cellular 
factors. This interaction strongly affects also the Tax-1-dependent, p300/CBP-
mediated viral transactivation (Clerc et al., 2008). HBZ inhibits, while Tax-1 activates, 
the classical Nuclear Factor kappa B (NFkB) pathway by inducing PDLIM2 expression 
which brings about proteasomal degradation of RelA. HBZ suppresses, while Tax-1 
activates,Wnt pathway by interacting with the disheveled-associating protein with a 
high frequency of Leucine residues (DAPLE) (Ma et al., 2013). HBZ inhibits 
production of Th1 cytokines (particularly IFN-γ) by interacting with NFAT and thus 
impairing cell-mediated immunity (Sugata et al., 2012). A number of effects suggest 
an important action of HBZ in supporting and/or maintaining the proliferation of 
HTLV-1 infected cells and by this the initiation and persistence of ATL. For example, 
the interaction of HBZ with JunD activates the telomerase by up-regulating the 
expression of hTERT (Kuhlmann et al., 2007).  
HBZ interacts with ATF3 and reduces the interaction of ATF3 with p53, possibly 
interfering with p53 signaling leading to apoptosis and thus increasing the potential of 
ATL cells to proliferate (Hagiya et al., 2011). 
 
 
 
 10 
 
 
 
Figure 6. Cellular proteins that interact with HBZ. The three domains of sHBZ corresponding to  
the AD, CD or bZIP domains, are portrayed as squares in three different colors while the cellular 
binding partners of HBZ are shown as rectangles with colors corresponding to the various HBZ 
domains they interact with. Cellular proteins that bind to more than one domain of HBZ are painted 
in multiple colors whereas those lacking such information are painted in dark grey. The major 
pathways that these interactions have impact on, either positive (+) or negative (−), are noted close to 
respective cellular proteins. (Ma et al., 2016) 
 
 
 
HBZ interacts with Smad3 and C/EBPα in a ternary complex which suppresses 
C/EBPα signaling pathway, again favoring proliferation of ATL cells. Moreover, the 
capacity of HBZ to participate in ternary complexes with Smad3 and its interacting 
factors, such as p300, may explain the up-regulation of TGFβ signaling pathway that 
is activated by Smad3-p300 (Figure 6). Interestingly TGFβ may increase the 
expression of FoxP3, a marker of regulatory T cells (Tregs) which can be infected by 
HTLV-1 (Zhao et al., 2011); this may predispose to the onset of ATL since the 
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CD4+Foxp3+ Treg cell phenotype has been found in ATL leukemic cells (Karube et al., 
2004) although this aspect is still controversial (Toulza et al., 2009). 
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2 AIM OF THE STUDY 
 
The aim of my study was to investigate in detail the expression and subcellular 
localization of endogenous HBZ protein in the context of  HTLV-1 infected patients 
and particularly in those who evolved toward the HTLV-1 associated disease 
HAM/TSP. Most of the studies related to HBZ have been performed to date in HBZ-
transfected cells that, for their nature, express HBZ protein in non physiological 
manner. This raises the possibility that the results obtained might bear limited 
biochemical and functional relevance. Only recently, by the use of the first reported 
monoclonal antibody against HBZ, 4D4-F3, generated in our laboratory it was possible 
to investigate for the first time the expression and the biochemical interaction with host 
factors of endogenous HBZ in HTLV-1 chronically infected cells, in ATL cell lines 
and, most importantly in fresh PBMCs of an ATL patients. The present work was set 
to determine whether I could detect and define by confocal microscopy the subcellular 
localization of endogenous HBZ in HAM/TSP. Moreover, the analysis was extended 
to more cases of ATL and to infected asymptomatic carriers (AC). In addition, by 
taking advantage of an immortalized CD4+ T cell line purified from HAM/TSP patient, 
we started to analyze the biological basis of the HBZ oncoprotein expression in a 
cellular model of HAM/TSP disease. 
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3 MATERIALS AND METHODS 
 
3.1 Cells 
 
Human embryonic kidney 293T cells (kindly provided by Prof. B.M. Peterlin, UCSF, 
San Francisco, USA) were cultured in Dulbecco’s modified Eagle medium (DMEM) 
containing 5 mM L-glutamine and supplemented with 10% fetal calf serum (FCS). 
ATL-2s is a T cell line derived from a leukemic patient kindly provided by Dr. 
Matsuoka, Japan (Takeda et al., 2004). Cells were maintained in RPMI-FCS 10%. 
Peripheral blood monuclear cells (PBMC) from healthy donors, HTLV-1+ 
asymptomatic carriers, HAM/TSP patients were purified by Ficoll-Paque TM PLUS 
(GE-Healthcare Bio-Science, Milan, Italy) of heparinated blood. PBMC from healthy 
donors were obtained by the Blood Transfusion Center, Ospedale di Circolo, 
Fondazione Macchi, Varese, whereas PBMC of HTLV-1-infected patients were 
obtained through the Biomedical Research Program approved by the Committee for 
the Protection of Persons, Ile-de-France II, Paris (2012-10-04 SC). All PBMC 
preparations were immediately frozen at -80°C and subsequently transferred in liquid 
nitrogen after 48–96 hours. The two ATL patients analyzed in this study, PH1393 and 
PH1505, were suffering from a typical acute ATL form characterized by high 
hyperlymphocytosis with lymphocyte count of 18.000/mm3 and 30.000/mm3, 
respectively, and with 79% and 80% of atypic lymphocytes, as evaluated by optical 
microscopy. Chronically HTLV-1-infected CD4_ T-cell line (CIB) (kindly provided 
by Dr. Claudine Pique_Institut Cochin. Paris, France) were generated by long-term 
culture in the presence of IL-2 of CD4+ T cells isolated from blood samples collected 
from a HAM/TSP patient (Ozden et al., 2004) . Chronic HTLV-1 expression was 
monitored by indirect immunofluorescence. 
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3.2 Transfection and treatments 
 
Plasmid encoding myc-tagged HBZ was a gift of Dr. Matsuoka, Univ. of Kyoto, Japan. 
Plasmid encoding Tax-1 was previously described (Tosi et al., 2011). 293T cells were 
cultured on glass coverslips  pre-coated with poly-L-lysine placed in 24 well plates. 
Cells were transfected with 0.2 μg of each plasmid by using FuGENE HD (Promega, 
Milan, Italy) in a ratio 3 μl/μg DNA. Cells were incubated with the transfection mixture 
until processed for confocal microscopy. Where indicated, the 293T cells or HAM/TSP 
PBMC were incubated with 20 nM leptomycin B (LMB; Sigma) or the vehicle 
methanol for 3 h at 37°C, 5% CO2. 
 
3.3 Immunofluorescence and confocal microscopy 
 
Frozen vials containing PBMC were thawed by immediate passage from liquid 
nitrogen to a water bath set at 37°C. Cells were washed with warm RPMI medium and 
processed for immunofluorescence and  confocal microscopy.  
For confocal microscopy, appropriate number of cells were cultured on glass coverslips 
pre-coated with poly-L-lysine (0.1gr/ml, Sigma) for five hours. The cells were then 
washed with 1x PHEM buffer, pH 6.9 (60 mM PIPES, 25 mM HEPES, 10mM EGTA, 
2mM MgCl2) three times, fixed in methanol 7 minutes at -20°C, and blocked with 1% 
BSA in 1x PHEM for 1h at room temperature (RT). Cells were then stained overnight 
with anti-HBZ 4D4-F3 monoclonal antibody (mAb), anti-Tax-1 mAb (clone 168 A51-
2 from the NIH AIDS Research and Reference Reagent Program), anti-vimentin rabbit 
polyclonal antibody (Santa Cruz Biotechnology, CA, USA), anti-CD4 rabit 
monoclonal antibody (clone EPR6855, ABCAM) and anti-CD19 rabbit monoclonal 
antibody (clone EPR5906, ABCAM), diluted in PHEM buffer containing 0.5% BSA. 
The slides were then washed five times with cold 1x PHEM and incubated in the dark 
for 2h at RT with the following secondary antibodies from Life Technology (Waltham, 
MA USA): goat anti-mouse IgG1 coupled to Alexa Fluor 546 to detect HBZ, goat anti-
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mouse IgG2a conjugated to Alexa Fluor 488 to detect Tax-1, and goat anti-rabbit IgG 
conjugated to Alexa Fluor 488 or to Alexa Fluor 546 to detect vimentin, CD4 or CD19. 
For co-staining with directly labelled antibodies, after extensive washing with 1x 
PHEM, anti-CD8 rabbit monoclonal antibody directly conjugated to Alexa Fluor 647 
(clone EP1150Y, ABCAM) and mouse anti-human CD25 monoclonal antibody 
directly conjugated to Alexa Fluor 488 (clone BC96, BioLegend) were added after the 
indirect immunofluorescence for two hours at room temperature. Similarly, after 
indirect immunofluorescence, the nuclei were stained by incubating the cells with 
DRAQ5 Fluorescent Probe (Thermo Scientific, Waltham, MA USA), for 30 min at 
room temperature. After washing, the slides were mounted on coverslips with the Fluor 
Save reagent (Calbiochem, Vimodrone (MI), Italy) and examined by a confocal laser 
scanning microscope (Leica TCS SP5; HCX PL APO objective lenses, 63x original 
magnification, numerical aperture 1.25). Images were acquired and analyzed by LAS 
AF lite Image (Leica Microsystem, Milan, Italy) and/or Fiji (Image J) softwares. 
 
3.4 Flow Cytometry Analysis 
 
Frozen vials containing PBMC were thawed by immediate passage from liquid 
nitrogen to a water bath set at 37°C. Cells were washed with warm RPMI medium and 
immediately processed for flow cytometry analysis with the BD FACSAria II™ 
apparatus. The following reagents were used: mouse anti-human HLA class I (clone 
B9.12); mouse anti-human HLA class II DR (clone D1.12), both revealed by FITC-
labelled rabbit anti-mouse IgG F(ab’)2 antiserum (Sigma, Milan, Italy); FITC mouse 
anti-human CD3 (clone (UCHT1, BD Pharmingen); FITC mouse anti-human CD4 
(clone RPA-T4, BD Pharmingen); PE-Cy5 mouse anti-human CD8a (clone RPA-T8; 
eBioscience, Milan, Italy); PE mouse anti-human CD16 (clone B73.1, eBioscience, 
Milan, Italy); FITC mouse anti-human CD19 (clone HIB19, BD Pharmingen) and 
phyco-erythrin (PE) mouse anti-human CD25 (clone M-A251, BD Pharmingen). 
Rendering and imaging were performed with FlowJo software (Version 7.6.5). 
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3.5 cDNA synthesis and QRT-PCR 
 
Total RNA was extracted from one million cells using Trizol (Invitrogen, Carlsbad, 
USA) and cDNA synthesized from 0.5 ?g RNA by using Iscript (Bio-Rad) according 
to the manufacturer’s protocol. PCR reactions were performed with an ABI Prism 7900 
HT Sequence Detection System by using 5 µl of each diluted RT sample (10 ng/µl) 
and 20 µl of diluted Taqman Universal PCR Master Mix (Applied Biosystems); each 
reaction was performed in duplicate. The cycling conditions comprised an initial step 
at 50°C for 2 min, denaturation at 95°C for 10 min, and 40 cycles at 95°C for 15 sec 
and 60°C for 1 min. The following primers were used for amplifying HBZ SPLICED1 
and HBZ UNSPLICED transcripts: 
HBZ-UNSPLICED-FW                             GCGGATCCATGGTTAACTTTGTATCT 
HBZ-UNSPLICED-RW                               GCGAATTCTTATTGCAACCACATCGCCTC 
HBZ-SPLICED1-FW                               GCGGATCCATGGCGGCCTCAGGGCTG 
HBZ-SPLICED1-RW                        GCGAATTCTTATTGCAACCACATCGCCTC 
The Ct values were calculated by using standard curves constructed from 5-fold serial 
dilutions of a plasmid containing the Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) amplicon, or HBZ amplicon. The absolute copy number of each transcript 
was determined and normalized for the copy number of the GAPDH.  
 
3.6 SDS/PAGE and Western Blotting 
 
293T, 293T myc-HBZ transfected, ATL and CIB cells were collected and lysed with 
lysis buffer containing 1% NP-40, 10mM Tris-Hcl pH 7.4, 150nM Nacl, 2mM EDTA, 
1uM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitors cocktail (sigma). 
Cell debris were removed by centrifugation at 14.000 rpm for 10 minutes at 4 °C  and 
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the supernatant were collected. Cell Lysate were analysed for the expression of HBZ 
protein in denaturating conditions by gel electrophoresis followed by western blotting. 
For the denaturating gel electrophoresis the lysates were diluted with 6x SDS-sample 
buffer (0.3M Tris-Hcl pH 6.8, 0.6 M DTT, 10% SDS, 0.6% bromophenol blue, 60% 
glycerol) and boiled for 3 minutes before loading on the gel. Protein were than 
separated by electrophoresis on 8% polyacrylamide gel containing 0.1% SDS and 
transferred into a nitrocellulose membrane (Amershamk Protran Premium 0.45 micron 
NC, Ge Healtcare) by electroblotting (360 mA for 1h) at 4 degrees. After blocking with 
5% non-fat dry milk in PBS for 1h at room temperature, the membrane was incubated 
with the primary antibody diluted in 5% non-fat dry milk in PBS, overnight at 4 °C 
under continuous agitation. The membrane was than washed three times for 10 minutes 
with PBS and than incubated with the secondary antibody solution ( HRP-conjugated 
goat anti mouse secondary antibody) for 2h at room temperature, under agitation. After 
3 washes with PBS, blots were developed by ECL (Supersignal West pico 
chemiluminescent substrate, Thermo Fisher Scientific).  
 
3.7 Immunoprecipation 
 
For immunoprecipitation 10 millions of  CIB, ATL cells and 3 million untransfected 
or myc-HBZ-transfected  293T cells  were lysed on ice for 50  minutes with IP lysis 
buffer containing 1% NP-40, 10mM Tris-Hcl pH 7.4, 150nM Nacl, 2mM EDTA, 1µM 
phenylmethylsulfonyl fluoride (PMSF) and protease inhibitors cocktail (Sigma). Cell 
lysates were centrifuged at 14000 rpm for 10 minutes and the supernatant were pre-
cleared with protein A Sepharose fast flow beads (GE Healtcare) for 30 minutes at 4 
degrees by rotation. To precipitate HBZ protein, after pre clearing, the cleared lysates 
were incubated with 1ug of anti-HBZ antibody (4D4-F3) for 1h on ice and then reacted 
with 50µl of protein A beads overnight at 4 degrees by rotation. The immune 
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precipitated proteins were analyzed by western blots using anti-HBZ monoclonal 
antibody. 
 
3.8 Immunohistochemistry 
 
Immunohistochemical studies were performed on 3µm formalin-fixed, paraffin-
embedded sections following standard procedures. Antigen retrieval was performed 
with a 10 min microwave treatment in 10 mM Citrate Buffer (pH 6) and after washing 
in TBS Triton Buffer (pH 7.4). Sections were incubated overnight at 4°C with the 4D4-
F3  anti-HBZ monoclonal antibody (1:1000 dilution of ascitic fluid). The sections were 
then incubated with biotinilated goat anti-mouse antibody for 2 h (Vector Laboratories, 
Burlingame, CA, USA) followed by ABC-peroxidase complex (Vector Laboratories) 
according to manufacturer’s protocol. The immunoreaction was developed with 3.3’-
diaminobenzidine tetrahydrochloride (DAB) (Sigma Aldrich, St. Louis, MO, USA) as 
chromogen. Nuclei were counterstained with Harris hematoxylin and finally sections 
were dehydrated and embedded in Pertex (Kaltek Srl, Padua, Italy).  
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4 RESULTS 
 
4.1 Phenotypic features of ATL cells and expression of HTLV-1 HBZ protein in 
PBMC of ATL patients 
 
To expand  previous studies performed in this laboratory  in ATL patients (Raval et al., 
2015), PBMC of two patients, PH1393 and PH1505, were investigated for the 
expression of cell surface markers by immunofluorescence and flow cytometry and for 
the expression of HBZ  by immunofluorescence and confocal microscopy. 
Results of cell surface phenotype are shown in Figure 7. Patients exhibited a surface 
phenotype of a T cell leukemia. (Figure 7). Indeed most of the cells were leukemic and 
expressed the CD4 marker. Interestingly, cells from patient PH1383 expressed high 
level of the CD25 T cell activation marker in a homogenous fashion, overlapping the 
cells with the CD4+ phenotype. CD25 marker was expressed at very low level, instead, 
in the PH1505 patient cells. Of note, while in PH1393 all cells were CD3 positive, 
PH1505 was negative for CD3. The cells of both patients were negative for CD8, CD16 
and CD19 surface markers. 
When the patients’ cells were analyzed for expression of HBZ, 80% and 83% of the 
cells from patient PH1393 and PH1505, respectively, were positive for HBZ (Table 1). 
HBZ was localized in speckle-like structures in the nucleus (Figure 8). Parallel staining 
for the nuclear marker DRAQ5, and for the cytoplasmic marker vimentin, confirmed 
the exclusive nuclear localization of HBZ. PBMC of the two ATL patients were also 
analyzed for the presence of Tax-1 protein; none of them showed positivity for this 
viral protein (Table 1). 
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4.2 Tax-1 but not HBZ is expressed in PBMC of asymptomatic carries. 
 
PBMC from the three asymptomatic carriers (AC), namely PH1614, PH1619 and 
PH1621, were similarly analyzed for their cell surface phenotype (Figure 9) and for the 
intracellular expression of HBZ and Tax.  Flow cytometric analysis indicated in certain 
patients limited differences in the expression of relevant lymphocyte subpopulation 
markers with respect to normal PBMC cells used as controls. An appreciable difference 
was in the expression, but not the proportion, of the CD4 cell marker, which was 
consistently reduced in all three AC. The significance of this finding will require 
further assessment in a higher number of cases.   
Interestingly, the PBMC of all three AC did not show any positivity for HBZ, when 
analyzed by immunofluorescence and confocal microscopy (Figure 10A), although 
they expressed Tax-1 in a small but distinctive proportion of cells: 11%, 1% and 6%, 
respectively (Table 1) with a preferential, although not exclusive, nuclear 
localization (Figure 10B).  
 
 
4.3 Cytoplasmic localization of HTLV-1 HBZ protein in PBMC of HAM/TSP 
patients 
 
In order to define the subcellular localization of endogenous HBZ in HAM/TSP, 
PBMC of four HAM/TSP patients, namely PH1485, PH1593, PH1601 and PH1624 
were studied by cells surface marker analysis, immunofluorescence and confocal 
microscopy analysis.  
When analyzed for relevant lymphocyte cell markers, all patients exhibited a cell 
surface expression similar to the one expressed by normal PBMC (Figure 11). 
Of particular relevance, instead, and in striking contrast with the HBZ nuclear 
localization in ATL (Raval et al., 2015), all four HAM/TSP patients presented an HBZ 
localization confined exclusively to the cytoplasm (Figure 12A) (Baratella et al., 2017).  
 21 
 
Parallel staining with DRAQ5, a nuclear marker, and with vimentin, a cytoplasmic 
marker, confirmed this exclusive HBZ cytoplasmic localization. HBZ appeared as 
discrete dots, similar in shape to the nuclear speckles found in PBMC of ATL patients. 
The percentage of HBZ positive cells was comprised between 4 to 11% of total PBMC 
in three of the four patients analyzed with the exception of patient PH1601 having only 
0,4% HBZ-positive cells (Table 1). PBMC from HAM/TSP patients were then 
analyzed for the expression and subcellular localization of Tax-1 protein. Tax-1 was 
expressed in 1%, 14% and 20% of the PBMC of PH1601, PH1485 and PH1624 
patients, respectively (Table 1). Tax-1 was undetectable in PH1593 PBMC. In patient 
PH1485 Tax-1 was localized in dot-like structures in the nucleus (Figure 12B). A 
proportion of these cells expressed Tax-1 also in the cytoplasm. In patient PH1624 
PBMC, Tax-1 was localized in the nucleus with a large proportion of these cells 
expressing Tax-1 also in the cytoplasm. Importantly, in this restricted series of patients, 
no cells were found to co-express HBZ and Tax-1 (Figure 12C). 
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4.4 HBZ in HAM/TSP stably resides in the cytoplasm and does not shuttle to 
and from the nucleus 
 
In order to assess whether the cytoplasmic localization of HBZ in PBMC of HAM/TSP 
patients is a stable feature or dynamic event resulting from a rapid recycling of the 
protein from the nucleus, PBMC from PH1624 patient were treated with Leptomycin 
B (LMB), an inhibitor of Cmr1-dependent nuclear export, and analyzed by 
immunofluorescence and confocal microscopy. Results clearly indicate that the HBZ 
cytoplasmic localization in PBMC of HAM/TSP was not affected by LMB 
treatment (Figure 13A). Conversely, as was previously shown in our laboratory 
(Forlani et al., 2016) this treatment resulted in a prominent nuclear retention of Tax-1 
protein in 293T cells transfected with a Tax-1-expression vector (Figure 13B). From 
these results, we conclude that in HAM/TSP patients, HBZ is specifically retained into 
the cytoplasm and does not shuttle into the nucleus throughout the exportin-dependent 
nuclear export. 
 
 
4.5 HBZ-positive cells in HAM/TSP representative PH1624 patient are found in 
the CD4+/CD25- T cell subpopulation 
 
In order to define the cellular subpopulation expressing the cytoplasmic HBZ protein 
in HAM/TSP patients, we analyzed in detail the PBMC of patient PH1624 displaying 
one of the highest number of HBZ-positive cells (9%). Analysis of cell surface markers 
by immunofluorescence and flow cytometry showed that this patient expressed CD3, 
CD4 and CD8 markers in 88%, 63% and 27% of PBMC, respectively. This phenotype 
was very similar to the one of PBMC from a normal donor. Interestingly the T cell 
marker CD25, known to be expressed in activated as well as in regulatory T (Treg) 
cells was not detected in PH1624 PBMC (Figure 11), whereas it was expressed at low 
amount in 4–5% of normal PBMC. The B cell compartment, as assessed by the 
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presence the CD19 marker, was represented in almost equal proportion of PH1624 
(10%) and normal (8%) PBMC. NK cells, as assessed by the CD16 marker, were 4% 
of PH1624 PBMC and 10% of normal PBMC. HLA class I was expressed in 100% of 
both PH1624 and normal PBMCs, and HLA class II was expressed in 15% and 18% 
of PH1624 and normal PBMC, respectively (Figure 11). 
Subsequently, confocal microscopy analysis was performed. Cytoplasmic HBZ was 
clearly detected in a significant proportion of CD4+ cells (Figure 14A). Indeed, 15% 
of CD4+ T cells were also HBZ positive. Considering that cytoplasmic HBZ was 
detected in 9% of the total PBMC of PH1624 patient, and that CD4+ T cell represented 
around 63% of the PBMC in this patient, it derives that virtually all HBZ+ cells are 
included in CD4+ T cell compartment. Cytoplasmic HBZ+ cells were virtually not 
detected in the CD8+ PBMC of PH1624 patient (Figure 14B). In fact, after careful 
analysis of more than one hundred CD8+ T cells, only one cell was found to co-express 
HBZ in its cytoplasm (Figure 14B). Confocal analysis of CD25 expression in PH1624 
patient’s PBMC confirmed that cells were negative for this marker (Fig. 15). Similarly, 
neither CD19+ B cells nor CD16+ NK cells were found to express cytoplasmic HBZ. 
Thus, in a representative HAM/TSP patient displaying a high percentage of HBZ-
positive cells, cytoplasmic HBZ is almost exclusively found in CD4+ T cells and these 
cells do not co-express the CD25 marker. 
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4.6 HBZ and Tax-1 expression in the HAM/TSP patient cell line CIB  
 
To confirm and better understand the peculiar distribution of the HBZ oncoprotein in 
the HAM/TSP pathology we took advantage of an immortalized CD4+ T cell line, 
designated CIB, obtained by continuous culturing in IL-2 of purified CD4+ T cells 
isolated from PBMC obtained from an HAM/TSP patient (Ozden et al., 2004).  
By immunohistochemistry and light field microscopy we assessed the distribution of 
the HBZ oncoprotein in this cells line with our 4D4-F4 anti HBZ antibody (Figure 16). 
Virtually all cells expressed HBZ and again the expression seemed to be confined to 
the cytoplasmic compartment. This finding was confirmed by more refined confocal 
microscopy analysis as it is shown in Figure 17. 
Biochemical experiments were then set up to assess the comparative amount of HBZ 
expressed in the CIB cell line with respect to the adult T cell leukemia-derived cell line 
ATL-2 (Figure 18). indicate that the degree of HBZ expression in the two cell lines 
was similar, although CIB cell line expressed an additional band of 20 kDa related to 
HBZ whose molecular nature is presently under investigation. Interestingly, and as 
previously shown (Raval et al., 2016) the total amount of endogenous HBZ expressed 
in either ATL-2 or CIB cell lines was much lower than the amount expressed in HBZ-
transfected 293T cells further emphasizing the notion that the conclusions derived from 
biochemical and functional correlates found in HBZ-transfected cells should be 
carefully reconsidered and framed in the context of endogenously expressing HBZ-
positive cells. 
CIB cells were subsequently analyzed for the expression of the HTLV-1 Tax-1 
oncoprotein as well. Interestingly, careful analysis by confocal microscopy of Tax-1 
expression in CIB cells showed that only 30% of the cells were positive for the viral 
protein (a representative Tax-1-positive cell is shown in Figure 19). Tax-1 displayed 
the characteristic speckle-like aspect and the localization was mostly cytoplasmic with 
few spots in the nucleus. Nevertheless, this level of Tax-1 expression was sufficient to 
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activate the NF-kB pathway as shown by the nuclear translocation of NF-kB p65 
(Figure  20). 
Since most of Tax-1 was found localized in the cytoplasm, I further investigated the 
possibility that in those CIB cells co-expressing Tax-1 and HBZ, the two protein co-
localized together. Confocal microscopy showed a clear distinct distribution of the two 
viral proteins in the cytoplasm, indicating that HBZ and Tax-1 do not interact each 
other in CIB cells (Figure 21). 
 
4.7 Spliced-1 and Unspliced HBZ are both expressed in HTLV-1 infected 
asymptomatic carriers and in HAM/TSP patients. 
 
As described in the Introduction, HBZ consists of two different forms derived from a 
spliced or an unspliced mRNA. In order to evaluate the possibility that a distinct 
splicing form could be implicated in the exclusive cytoplasmic distribution of HBZ 
protein found in HAM/TSP patients, RT-PCR of spliced and unspliced forms was 
carried out  in mRNA preparations from PBMC of 7 HAM/TSP patients, 2 AC, as well 
as from CIB and ATL-2s leukemic cells. 
The results depicted in Figure 22 indicate that both forms are expressed in the various 
cell samples analyzed including the 7 PBMC samples of HAM/TSP patients with a 
tendency of the spliced form to be more expressed in HAM/TSP samples although with 
no statistical significance. This difference is more pronounced in samples derived from 
the two asymptomatic carriers (AC) analyzed, although a more extensive number of 
cases should be analyzed before drawing conclusions on the real meaning of this 
finding. 
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5 DISCUSSION AND FUTURE PERSPECTIVES 
 
Infection by HTLV-1 generally leads to a state of asymptomatic carrier which may last 
for the entire life. However, in 3–7% of individuals a very severe form of 
leukemia/lymphoma or a chronic progressive neurological disease can develop as 
result of the infection. The oncogenic progress leading to ATL has been mainly 
attributed to the viral transactivator Tax-1 that hijacks the basic mechanisms of control 
of cellular homeostasis (Giam and Semmes, 2016). Nevertheless, only 40% of ATL 
patients can express Tax-1 whereas all of them express HBZ, an event that has been 
interpreted as an involvement of Tax-1 in the first phases of oncogenic process and of 
HBZ in the maintaining of leukemic state (Matsuoka and Yasunaga, 2013). While 
recent data have unambiguously demonstrated the nuclear localization of endogenous 
HBZ in ATL cells and in chronically infected cell lines (Raval et al., 2015), no data 
were available on the endogenous expression and subcellular localization of HBZ in 
patients affected by HAM/TSP. My PhD thesis was focused particularly in assessing 
the expression and subcellular distribution of HBZ protein in PBMC of patients 
affected by the HAM/TSP disease and in comparing it to asymptomatic carriers and 
patients affected by ATL. I was able to demonstrate that a discrete percentage, up to 
11%, of PBMC from HAM/TSP patients express HBZ and that this expression is 
exclusively confined to the cytoplasm. Cytoplasmic HBZ appears distributed in dots 
similar to the nuclear speckle-like structures observed in leukemic cells of ATL 
patients, sometimes dispersed all over the cytoplasm, sometimes concentrated in a 
restricted area of it (Baratella et al., 2017). This unprecedented finding was further 
confirmed by the study of an IL-2-dependent T cell line derived from a HAM/TSP 
patients, the CIB cell line, in which it was also possible to conduct additional 
preliminary biochemical analysis to compare the amount of HBZ expressed in 
HAM/TSP cells compared to ATL-2s leukemic cells. This analysis showed a similar 
expression in the two cell lines and further demonstrated the relatively much lower 
expression of endogenous HBZ as compared to the expression observed in HBZ-
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transfected cells, as was previously observed in our laboratory (Raval et al., 2015). This 
finding should lead to caution in drawing conclusions related to the biochemical 
interaction of HBZ with other intracellular partners and consequent functional 
correlates of these interactions in vivo when these findings are obtained in transfected 
cells in which overexpression of HBZ may alter the interpretation of the data.  
The exclusive cytoplasmic distribution of HBZ in PBMC of HAM/TSP patients was 
not due to a preferential shuttling of the protein from the nucleus to cytoplasm, since 
treatment of the cells with Leptomycin B, a drug that blocks the CRM1-dependent 
nuclear-cytoplasmic shuttling of the proteins, did not result in even partial segregation 
of the protein into the nucleus, strongly indicating that HBZ is a cytoplasmic resident, 
non migrating protein in HAM/TSP patients. 
It has been recently described the existence of amino acid variations in the HBZ protein 
both in asymptomatic carriers and HAM/TSP patients, identified in the activation 
domain and in the nuclear localization signal sequence (Mota-Miranda et al., 2013). 
Thus it might be possible that HBZ sequence variation may influence the subcellular 
localization of the protein. However, this should not certainly involved a possible 
exclusive expression of either one of the two major forms of HBZ described, that is the 
unspliced and the spliced form, as both mRNAs of these forms were present in cells of 
HAM/TSP patients, as well as in cells of leukemic patients. Thus other mechanism 
should be responsible of the exclusive cytoplasmic distribution of HBZ in HAM/TSP. 
Future studies on possible partner interactors of HBZ in the cytoplasm will certainly 
help in clarifying this aspect. 
An additional interesting finding reported in the present study concerns the expression 
and localization of HTLV-1 Tax-1 at the single cell level. In PBMC of HAM/TSP 
patients, when detectable, Tax-1 was localized mostly in the nucleus and in a variable 
proportion of the cells in both nucleus and cytoplasm. Importantly, it was never 
expressed in the same cells expressing HBZ. While uncoupling of Tax-1 and HBZ 
expression is rather common in ATL patients (Matsuoka and Jeang, 2007; Takeda et 
al., 2004),(Satou et al., 2006) , the mutually exclusive expression of either HBZ or Tax-
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1 proteins at the single cell level has never been reported. The molecular basis of this 
event in cells of HAM/TSP patients is unknown at present, and certainly will be the 
focus of our future investigation. It is tempting to speculate that this finding may be 
relevant at the functional level and particularly in the immune recognition of HTLV-1 
infected cells. The HBZ cytoplasmic localization, possibly in extra-endosolic 
compartments, may not be appropriate to the generation of peptides that can efficiently 
bind MHC class I molecules for presentation to, and scrutiny by cytotoxic T cells 
(CTLs). This may explain the relatively low level of HBZ-specific CTLs in HAM/TSP 
(Macnamara et al., 2010) in conjunction with the unsatisfactory lytic efficiency of 
HBZ-specific CTLs with respect to the strong recognition and lytic efficiency of Tax-
1-specific CTLs (Hilburn et al., 2011). A note of caution, however, should be expressed 
in relation to the mutually exclusive expression of HBZ and Tax-1 in HAM/TSP 
disease. Indeed the model cell line CIB derived from a patient with HAM/TSP was 
found to coexpress HBZ and Tax-1. The reason of this striking different aspect of CIB 
with respect to fresh PBMCs is at present under investigation. A possible explanation 
could be that in vitro growing of CIB may have altered the pattern of expression and 
subcellular distribution of Tax-1 in a cell that at the origin did not express Tax-1 at all. 
Alternatively, CIB is indeed one of those very few cells that co-expressed HBZ and 
Tax-1 from the beginning and for this reason may have had growth advantage in culture 
when isolated from the patient.  Whatever the mechanism underlying this event, it was 
clear from the data presented in this thesis that HBZ and Tax-1 did not co-localize in 
the same speckles and thus they could not significantly interact each other. 
Additional confocal microscopy analysis of PBMC of a representative HAM/TSP 
patient PH1624 clearly showed that the major, if not the exclusive, HBZ+ cell 
subpopulation was represented by CD4+ cells. After counting a large number of CD8+ 
PH1624 cells, only 1 was found to express cytoplasmic HBZ. Thus, if from one side 
this result indicates that CD8+ cells can be infected by HTLV-1 and express HBZ in 
the HAM/TSP patients, this event is extremely rare as compared to the frequency of 
HBZ+/CD4+ cells. PBMC of HAM/TSP patient PH1624 did not reveal the presence 
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of CD25+ T cells by FACS analysis. Further refinement by confocal microscopy 
analysis confirmed the absence of CD4+/CD25+ T cells, a subset that includes 
regulatory T cells (Treg). Although CD4+/CD25+ Tregs can be infected by HTLV-1 
and HAM/TSP patients have been shown to have a high number of CD4+/CD25+ 
Tregs with impaired function (Araya et al., 2011) as well as HBZ mRNA expression 
levels comparable to those observed in ATL (Yamano et al., 2009), our result indicate 
that in HAM/TSP patients HBZ protein expression can be easily found in CD4+ T cells 
not displaying the classical phenotype of Treg cells. Additional studies are certainly 
required to further detail the phenotype and the functional correlate of CD4+ T cells 
expressing HBZ protein in HAM/TSP patients. 
In conclusion, based on the results presented in this Thesis, we propose that HBZ 
cytoplasmic localization can be considered as a bona fide biomarker of HTLV-1-
derived HAM/TSP pathology. 
Although several studies have been focused at clarifying the role of HBZ in HTLV-1-
associated diseases, much research is still required to clearly define the involvement of 
HBZ in the molecular and cellular events that lead to the distinct outcome of viral 
infection, whether evolving versus the leukemia/lymphoma or versus the 
neuroinflammatory disorders. 
The discovery of HBZ has led to important new research avenues with potential 
association with HTLV-1-associated diseases (Barbeau et al., 2013). In fact, ATL cells 
from infected patients consistently express HBZ and substantial evidence points 
toward HBZ implication in viral persistence and ATL cell survival. Our evidences 
further suggest that HBZ in the cytoplasmic compartment can represent a potential 
marker of a different pathological state, namely HAM/TSP. Several cellular factors are 
known to interact with HBZ, and it will be extremely important to analyze such 
interactions in the context of HAM/TSP and comparing them to the ones in  ATL 
disease,  in relation to the different cellular localizations HBZ protein. These 
comparative studies will provide a better understanding as to the mechanism by which 
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HBZ is involved in HAM/TSP development, which might also lead to new potential 
HAM/TSP treatment. 
With the above limitations in mind, the cumulative studies presented in this thesis 
suggest, however, a possible roadmap in the evolution of HTLV-1 infection (Figure 
23). We may think that primary HTLV-1 infection is characterized by the expression 
of Tax-1 (this stage may be observed in PBMC of still asymptomatic patients), 
followed by the possible transient co-expression of HBZ (yet to be demonstrated). As 
we have no specific demonstration of this intermediate step, we do not know whether 
HBZ protein can localize in the nucleus, cytoplasm or both cellular compartments at 
these early stages of infection. Immediately after, a compartmentalization of HBZ in 
the cytoplasm can take place in case of evolution of the infection towards HAM/TSP. 
At this stage, the evolving pathology can either present a concomitant Tax-1 expression 
in the same cells (the CIB cell may represent one of these cases), or a mutually 
exclusive expression of Tax-1 and HBZ in different cells, as we observed in our 
patients.  Conversely, in case of evolution toward the leukemic stage, HBZ will be 
expressed always and only in the nucleus with or without the co-expression of Tax-1. 
This hypothetical scheme is useful to test several additional hypotheses and investigate 
previously unforeseen mechanisms. For example, can we hypnotize a stage in which 
HBZ is compartmentalized in the cytoplasm still without clinical signs of neurological 
disease and use this parameter also as a prognostic marker of future development 
toward HAM/TSP. Moreover, we believe, that now we can experimentally investigate 
what are the molecular mechanisms that drive the distinct nuclear or cytoplasmic 
localization of the HBZ protein, the specific interactors that retain HBZ in the two 
different cellular compartments and if are these mechanisms related to the onset and/or 
the persistence of the distinct pathologies. 
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Figure 7. Expression of cells surface markers in PBMC of ATL patients PH1393 
and PH 1505 and healthy control. The expression of HLA class I, HLA class II DR, CD3, 
CD4, CD8, CD25, CD19, and CD16 surface molecules on PBMC from ATL patient PH1393, 1505 
and a healthy control was assessed by immunofluorescence and flow cytometry with antibodies 
specific for the various markers. Results are expressed as relative number of cells (ordinate) versus 
the mean intensity of fluorescence in arbitrary units (abscissa). In each histogram, negative controls, 
obtained by staining the cells with an appropriate isotype-matched antibody, are depicted as dashed 
line. The percentage of positive cells for the cell surface marker analyzed are indicated on the top 
right of every panel. 
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Figure 8. Subcellular localization of endogenous HBZ and Tax-1 in PBMC of ATL 
patients. PBMC of two ATL patients (PH1393 and PH1505) were stained with the anti-HBZ 4D4-
F3 mAb, followed by Alexa Fluor 546-conjugated goat anti-mouse IgG1antibody to detect the HBZ 
protein and analyzed by confocal microscopy. Specific counterstaining of nucleus or cytoplasmic 
compartments was performed by using DRAQ5 fluorescence probe or anti-vimentin antibody, 
respectively. At least 300 cells were analyzed; a representative cell for HBZ staining is shown for 
each patient. 
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Figure 9. Expression of cells surface markers in PBMC of AC individuals and 
healthy control. The expression of HLA class I, HLA class II DR, CD3, CD4, CD8, CD25, CD19, 
and CD16 surface molecules on PBMC from AC patient PH1614, PH 1619 and PH 1621 and a healthy 
control was assessed by immunofluorescence and flow cytometry with antibodies specific for the 
various markers. Results are expressed as relative number of cells (ordinate) versus the mean intensity 
of fluorescence in arbitrary units (abscissa). In each histogram, negative controls, obtained by staining 
the cells with an appropriate isotype-matched antibody, are depicted as dashed line. The percentage 
of positive cells for the cell surface marker analyzed are indicated on the top right of every panel. 
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Figure 10. Lack of endogenous HBZ, but not of Tax-1, detection in PBMC of 
HTLV-1 positive asymptomatic carriers. (A) PBMC of three HTLV-1-positive 
asymptomatic carriers (PH1614, PH1619, and PH1621) were stained with the anti-HBZ 4D4-F3 and 
(B) the anti-Tax-1 A51-2 mAbs, followed by Alexa Fluor 546-conjugated goat anti-mouse 
IgG1antibody to detect HBZ protein (red), or by Alexa Fluor 488-conjugated goat-anti-mouse IgG2a 
to detect Tax-1 (green), and analyzed by confocal microscopy. Specific counterstaining of nucleus or 
cytoplasmic compartments was performed by using DRAQ5 fluorescence probe to detect the nucleus 
and anti-vimentin rabbit polyclonal antibody followed by goat anti-rabbit IgG conjugated to Alexa 
Fluor 488 (green, panel A) or to Alexa Fluor 546 (red, panel B) to stain the cytoplasmic compartment. 
At least 300 cells were analyzed; a representative cell is shown for each patient. 
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Figure 11. Expression of cells surface markers in PBMC of HAM/TSP patients 
and healthy control. The expression of HLA class I, HLA class II DR, CD3, CD4, CD8, CD25, 
CD19, and CD16 surface molecules on PBMC from AC 1485, 1593, 1601,1624 and a healthy control 
was assessed by immunofluorescence and flow cytometry with antibodies specific for the various 
markers. Results are expressed as relative number of cells (ordinate) versus the mean intensity of 
fluorescence in arbitrary units (abscissa). In each histogram, negative controls, obtained by staining 
the cells with an appropriate isotype-matched antibody, are depicted as dashed line. The percentage 
of positive cells for the cell surface marker analyzed are indicated on the top right of every panel. 
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Figure 12. Subcellular localization of endogenous HBZ and Tax-1 in PBMC of 
HAM/TSP patients. (A) PBMC of four HAM/TSP patients (PH1485, PH1593, PH1601, and 
PH1624) were stained with the 4D4-F3 anti-HBZ mAb followed by Alexa Fluor 546-conjugated goat 
anti-mouse IgG1 antibody (red) and (B) with the A51-2 anti-Tax-1 mAb followed by Alexa Fluor 
488-conjugated goat-anti-mouse IgG2a antibody (green), and analyzed by confocal microscopy. 
Specific counterstaining of nucleus or cytoplasmic compartments was performed by using DRAQ5 
fluorescence probe to detect the nucleus and anti-vimentin rabbit polyclonal antibody followed by 
goat anti-rabbit IgG conjugated to Alexa Fluor 488 (green, panel A) or to Alexa Fluor 546 (red, panel 
B) to stain the cytoplasmic compartment. At least 300 cells were analyzed; a representative cell for 
HBZ or for Tax-1 staining is shown for each patient.(C) Low magnification field to show the co-
existence of cells mutually exclusive for the expression of cytoplasmic HBZ and Tax-1 in PBMC of 
patient PH1624. Cells were co-stained with 4D4-F3 anti-HBZ mAb and with A51-2 anti-Tax-1 mAb 
followed by specific secondary antibodies staining as described in (A) and (B). 
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Figure 13. In HAM/TSP patient PBMC, HBZ is a resident cytoplasmic protein 
and does not shuttle to the nucleus throughout the exportin system. (A) PBMC of 
HAM/TSP patient PH1624 were either treated (+ LMB) or untreated (- LMB) with LMB, an inhibitor 
of nuclear export, before fixing and staining with the anti-HBZ 4D4-F3 mAb followed by Alexa Fluor 
546-conjugated goat anti-mouse IgG1antibody (red). (B) As control of inhibition of nuclear export 
by LMB, 293T cells transfected with the plasmid coding for Tax-1 viral protein were treated with 
LMB (+LMB) or left untreated (-LMB). Cells were fixed and stained with A51-2 anti Tax-1 mAb 
followed by Alexa Fluor 488-conjugated goat-anti-mouse IgG2a (green), and analyzed by confocal 
microscopy. DIC represents the differential interference contrast image. 
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Figure 14. HBZ is preferentially expressed in CD4+ T cells of HAM/TSP patient 
PH1624. Confocal microscopy analysis of PBMC from HAM/TSP patient PH1624. (A) co-staining 
with the 4D4-F3 anti-HBZ mAb followed by Alexa Fluor 546-conjugated goat anti-mouse IgG1 
antibody (red) and with the anti-CD4 mAb followed by Alexa Fluor 488-conjugated goat-anti-rabbit 
IgG antibody (green); upper panels, extended field; lower panels, enlarged field focused on the single 
cell depicted in the square of the left upper panel and positive for both CD4 and HBZ. (B) co-staining 
with the 4D4-F3 anti-HBZ mAb followed by Alexa Fluor 546-conjugated goat anti-mouse IgG1 
antibody (red) and with the anti-CD8 rabbit monoclonal antibody directly conjugated to Alexa Fluor 
647 (blue); upper panels depict extended fields with CD8+ cells negative for HBZ; middle panels, 
extended fields with many CD8+ cells negative for HBZ and the single CD8+/HBZ+ cell (square); 
lower panels, enlarged field on the single CD8+/HBZ+ cell. 
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Figure 15. Lack of CD25+ cell in PBMC of patient PH1624, as assessed by 
confocal microscopy. PBMC of HAM/TSP patient PH1624 and of healthy control were co-
stained with the anti-HBZ 4D4-F3 mAb followed by Alexa Fluor 546-conjugated goat anti-mouse 
IgG1 antibody (red) and with the anti-CD25 monoclonal antibody directly conjugated to Alexa Fluor 
488 (green) and analyzed by confocal microscopy. Upper left panel shows the negativity of CD25 
staining in PH1624 patient as compared with a positive cell for the same marker in PBMC of healthy 
control (PBMC, lower left panel). 
 
 
 
 
 41 
 
 
 
 
 
Figure 16. Immunohistochemical (IHC) staining of HBZ ectopically expressed in 
293T and endogenously expressed in CIB cells. 293T. Cells were stained with 4D4-F3 
anti-HBZ mAb. All CIB cells show positivity for HBZ (brown staining). Non-transfected 293T and 
Jurkat T cells were used as negative control while HBZ transfected 293T cells were used as positive 
control of HBZ expression (cells with brown staining). 
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Figure 17. Cytoplasmic localization of endogenous HBZ in CIB cells. CIB cells were 
stained with the 4D4-F3 anti-HBZ mAb followed by Alexa Fluor 546-conjugated goat anti-mouse 
IgG1 antibody (red). Specific counterstaining of nucleus or cytoplasmic compartments was 
performed by using DRAQ5 fluorescence probe to detect the nucleus and anti-vimentin rabbit 
polyclonal antibody followed by goat anti-rabbit IgG conjugated to Alexa Fluor 488 to stain the 
cytoplasmic compartment. At least 1000 cells were analyzed. 
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Figure 18. HBZ is expressed in ATL and CIB cells line in a similar amount. Cell 
extracts from ATL (line 1) and CIB (Line 2) cells were immunoprecipitated (IP) with anti-HBZ 
monoclonal antibody and the immunocomplex  were analyzed by western blotting with anti-HBZ 
monoclonal antibody. Cell lysates of 293T cells expressing (293T HBZ) (line 4) or not (293T) (line 
3) HBZ were analysed by western blotting with anti-HBZ monoclonal antibodies. 
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Figure 19. Subcellular localization of endogenous Tax-1 in CIB cells. CIB cells were 
stained with the A51-2 anti-Tax-1 mAb followed by Alexa Fluor 488-conjugated goat-anti-mouse 
IgG2a antibody (green), and analyzed by confocal microscopy. Specific counterstaining of nucleus 
or cytoplasmic compartments was performed by using DRAQ5 fluorescence probe to detect the 
nucleus. Two representive cells are shown. At least 100 cells were analyzed. 
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Figure 20.  Tax-1 expression in  CIB cells can induce RelA migration in the 
nucleus of CIB cells. Cells were co-stained with anti p65 mAb followed by Alexa Fluor 546-
conjugated goat anti-rabbit IgG antibody (light blue) and with A51-2 anti-Tax-1 mAb followed by 
Alexa Fluor 488-conjugated goat-anti-mouse IgG2a antibody (green) and analyzed by confocal 
microscopy. Two representative fields are shown. The upper series of panels focuses on a single cell. 
The bottom series of panels shows seven cells. 
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Figure 21. Co-expression of endogenous HBZ and Tax-1 in CIB cells in distinct 
cytoplasmic compartments. Representative image of HBZ and Tax-1 co-expression in CIB 
cells. Cells were co-stained with 4D4-F3 anti-HBZ mAb followed by Alexa Fluor 546-conjugated 
goat anti-mouse IgG1 antibody (red) and with A51-2 anti-Tax-1 mAb followed by Alexa Fluor 488-
conjugated goat-anti-mouse IgG2a antibody (green ) and analyzed by confocal microscopy. A 
representative cell is shown. 
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Figure 22. mRNA expression levels of Unspliced and Spliced-1 HBZ in ATL and 
CIB cell lines and in AC and HAM/TSP patients. mRNA levels of both unspliced and 
spliced HBD isoforms were analyzed in PBMC isolated from ATL, AC and HAM/TSP patients by 
QRT-PCR.  Bar graphs show normalized copy numbers of the different mRNAs analyzed, as 
indicated in Materials and Methods. 
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Figure 23. A hypothetical model of disease progression in HTLV-1 infected 
people. The model is based on the expression and localization of Tax-1 and HBZ proteins at the 
single cell level. Primary HTLV-1 infection is associated to the expression of Tax-1. The progression 
of the disease leads to a different stage characterized by the concomitant expression of Tax-1 and 
HBZ. The subsequent localization of HBZ in the nucleus (nuHBZ) or the cytoplasm (cyHBZ) 
differentiates  the disease versus the leukemic or the inflammatory state. 
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Table 1. Percent and subcellular distribution of HBZ+ and Tax-1+ PBMC in HTLV-1 associated 
pathologies. 
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